12 July 2019 - - Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) has launched an over-the-counter store-brand equivalent of Mucinex D Extended Release Tablets in two strengths, Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg, and Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg, in the United States market, as approved by the US Food and Drug Administration (USFDA), the company said.
Dr. Reddy's OTC Guaifenesin and Pseudoephedrine HCl is used to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, and upper respiratory allergies; temporarily restore freer breathing through the nose; promote nasal and/or sinus drainage; and temporarily relieve sinus congestion and pressure.
The Mucinex D brand and store brands had combined US sales of approximately USD71 m MAT for the most recent twelve months ending in May 2019 according to IRI.
Dr. Reddy's OTC Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg is available in 24-count packages. Dr. Reddy's OTC Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg is available in 18- and 36-count packages.
Mucinex is a trademark of RB HEALTH LLC
Dr. Reddy's Laboratories is an integrated pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.